Balla, J

Bidiga, L

Dezső, B

Diószegi, Á

Nagy-Vincze, M

Nánásy-Vass, M

Soltész, P

Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)

Szekanecz, Z

Szodoray, P

Tarr, T

Veisz, R

Lupus

Antiphospholipid syndrome is characterized by multiple arterial and/or venous thrombotic events, recurrent fetal losses in the presence of antiphospholipid antibodies (aPL). Catastrophic antiphospholipid syndrome is a life-threatening, rare subset of antiphospholipid syndrome when the thrombotic events affect at least three organs, and clinical manifestations develop simultaneously or within a week. Diagnostically, small vessel occlusions can be detected by histopathology in the presence of aPL. Our case report describes an 18-year-old man who has been treated for antiphospholipid syndrome associated with systemic lupus erythematosus (SLE) since 2011. The clinical findings were dominated by recurrent deep vein thrombosis, and severe proteinuria caused by lupus nephritis, accompanied by mild serological and laboratory findings. The patient was hospitalized in March 2014 because of severe thrombocytopenia and infective diarrhoea. At this time the renal functions deteriorated rapidly. Simultaneously, left upper extremity paresis was observed; computed tomography showed ischaemic lesions in the territory of the middle cerebral artery. Abdominal discomfort and pain occurred. On computed tomography scan ischaemic lesions were seen in the spleen, the right kidney and the coeliac trunk. Laboratory and serological findings verified the presence of aPL and anti-DNA antibodies, anaemia and thrombocytopenia. Based on the above-mentioned clinical and laboratory findings, the diagnosis of catastrophic antiphospholipid syndrome was established. Anticoagulation, corticosteroids and plasma exchange treatment, as well as haemodiafiltration were initiated. Although the thrombotic cascade decelerated following these interventions, we could not see an improvement in the renal function. Rituximab treatment was started, leading to a significant improvement in renal function. After 5 weeks of treatment the patient was discharged from hospital.</jats:p

Á Diószegi

T Tarr

M Nagy-Vincze

M Nánásy-Vass

R Veisz

L Bidiga

B Dezső

J Balla

P Szodoray

Z Szekanecz

P Soltész

Crossref

Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment

Diószegi, Ágnes

Tarr, Tünde

Nagy-Vincze, Melinda

Vass, Melinda

Veisz, Richárd

Bidiga, László

Dezső, Balázs

Balla, József

Szodoray, Péter

Szekanecz, Zoltán

Soltész, Pál

DEA University of Debrecen Electronic Archive

https://dea.lib.unideb.hu/dea/bitstream/handle/2437/250168/lupus.pdf?sequence=4&isAllowed=y

Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment

Abstract

Similar works

Full text

Available Versions

Crossref

DEA University of Debrecen Electronic Archive